Colorectal Cancer: Review of clinical candidates.
By Aine Slowey, Lead Analyst
10 July 2014
I am the Lead Analyst for cardiovascular and metabolic diseases at Datamonitor Healthcare. I have a DPhil in Organic Che...
Read full bio
With the colorectal cancer market becoming increasingly crowded, it is important to understand how the three Phase III pipeline therapies will have to differentiate themselves from marketed drugs in order to gain uptake.
Datamonitor Healthcare has provided a review of clinical candidates, Cyramza, Imprime PGG and OncoVax, which are in development for colorectal cancer across the US, Japan and five major EU markets.
How will our colorectal cancer pipeline benefit you?
- Gain competitive insight
Investigate the commercial and clinical attributes of all three Phase III pipeline therapies, allowing you to compare them to one another and the therapies that are already commercially successful on the market.
- Identify investment opportunities
Explore how the pipeline therapies are combining with other marketed therapies to overcome challenges within the colorectal cancer market and their potential commercial success, allowing you to identify the key investment areas.
- Explore market gaps
Assess where potential market gaps occur, for example in the adjuvant treatment setting, and how pipeline therapies are targeting these niches, enabling you to identify any unmet needs within the market.
Key questions answered:
- How will Cyramza fair against competing VEGF targeted therapies already on the market?
- How will immunotherapies, a new class of drug to colorectal cancer, perform once launched onto the market?
- What impact will the Phase III pipeline therapies have on market leader Avastin?
|Drug List:||Companies Mentioned:|
Posted in Oncology.